[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2] HIRSCH F R,SCAGLIOTTI G V,MULSHINE J L,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311.
[3] RASOOL R U,NAYAK D,CHAKRABORTY S,et al.Differential regulation of NM23-H1 under hypoxic and serum starvation conditions in metastatic cancer cells and its implication in EMT[J].Eur J Cell Biol,2017,96(2):164-171.
[4] ZHENG Z,TIAN R,WANG P.Roles of KAI1 and nm23 in lymph angiogenesis and lymph metastasis of laryngeal squamous cell carcinoma[J].World J Surg Oncol,2017,15(1):211-216.
[5] 张炜,郭万华,李爱梅,等.中晚期非小细胞肺癌骨转移与EGFR基因突变相关分析[J].东南大学学报(医学版),2018,37(4):711-715.
[6] POTEL C M,FASCI D,HECK A J R.Mix and match of the tumormet astasis suppressor Nm23 protein isoforms in vitro and in vivo[J].FEBS J,2018,285(15):2856-2868.
[7] NIE M,QIN Y,ZHU J,et al.Correlation between ultrasonic features and expression levels of C-erbB-2,VEGF and nm23 in breast cancer[J].Oncol Lett,2018,16(2):1701-1707.
[8] OZTURK E,AKSOY S A,UGRAS N,et al.Coexistence of MACC1 and NM23-H1 dysregulation and tumor budding promise early prognostic evidence for recurrence risk of early-stage-colon cancer[J].APMIS,2018,126(2):99-108.
[9] 申潞艳,康晓征,孙宇,等.非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存[J].中国肺癌杂志,2016,19(3):147-152.
[10] 刘珍,苏小岩,胡艳,等.调强放疗单用与联合化疗对不同亚组鼻咽癌远期疗效的影响[J].热带医学杂志,2016,16(5):654-657.
[11] O'DONNELL J S,MASSI D,TENG M W L,et al.PI3K-AKT-mTOR inhibition in cancer immunotherapy,redux[J].Semin Cancer Biol,2018,48:91-103.
[12] GUERRERO-ZOTANO A,MAYER I A,ARTEAGA C L.PI3K/AKT/mTOR:role in breast cancer progression,drug resistance,and treatment[J].Cancer Metastasis Rev,2016,35(4):515-524.
[13] 王峰,李梅,朱建伟,等.miRNA-221在行完全切除术非小细胞肺癌中的表达及患者生存分析[J].东南大学学报(医学版),2016,35(3):332-336.
[14] 周霖,薛兴阳.Ⅰ期非小细胞肺癌病灶中nm23的表达及淋巴结微转移研究[J].中国肿瘤外科杂志,2016,8(4):254-256,259.
[15] 唐泽飞,李春鸣.nm23重组质粒与肿瘤关系研究进展[J].中华实用诊断与治疗杂志,2016,30(1):12-14. |